GENMAB A/S (GE9.DE) Stock Price & Overview
FRA:GE9 • DK0010272202
Current stock price
The current stock price of GE9.DE is 235.3 EUR. Today GE9.DE is down by -0.25%. In the past month the price decreased by -0.47%.
GE9.DE Key Statistics
- Market Cap
- 15.118B
- P/E
- 15.90
- Fwd P/E
- 18.72
- EPS (TTM)
- 14.80
- Dividend Yield
- N/A
GE9.DE Stock Performance
GE9.DE Stock Chart
GE9.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GE9.DE.
GE9.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GE9.DE. GE9.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
GE9.DE Earnings
On February 18, 2026 GE9.DE reported an EPS of 2.13 and a revenue of 1.06B. The company missed EPS expectations (-39.11% surprise) and beat revenue expectations (0.19% surprise).
GE9.DE Forecast & Estimates
27 analysts have analysed GE9.DE and the average price target is 307.95 EUR. This implies a price increase of 30.88% is expected in the next year compared to the current price of 235.3.
For the next year, analysts expect an EPS growth of -15.07% and a revenue growth 18.34% for GE9.DE
GE9.DE Groups
Sector & Classification
GE9.DE Financial Highlights
Over the last trailing twelve months GE9.DE reported a non-GAAP Earnings per Share(EPS) of 14.8. The EPS decreased by -2.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.89% | ||
| ROA | 7.48% | ||
| ROE | 16.47% | ||
| Debt/Equity | 0.88 |
GE9.DE Ownership
GE9.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.73 | 40.051B | ||
| 1AE | ARGENX SE | 26.69 | 39.989B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.659B | ||
| 2X1 | ABIVAX SA | N/A | 8.034B | ||
| ABVX | ABIVAX SA | N/A | 8.018B | ||
| GXE | GALAPAGOS NV | N/A | 1.691B | ||
| GLPG | GALAPAGOS NV | N/A | 1.687B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 981.136M | ||
| IVA | INVENTIVA SA | N/A | 980.098M | ||
| PHIL | PHILOGEN SPA | 17.77 | 649.128M | ||
| GNFT | GENFIT | 846.08 | 431.525M | ||
| FYB | FORMYCON AG | N/A | 329.015M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GE9.DE
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
IPO: 2000-10-01
GENMAB A/S
Carl Jacobsens Vej 30
Valby DK
Employees: 3029
Phone: 4570202728
GENMAB A/S / GE9.DE FAQ
Can you describe the business of GENMAB A/S?
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Can you provide the latest stock price for GENMAB A/S?
The current stock price of GE9.DE is 235.3 EUR. The price decreased by -0.25% in the last trading session.
What is the dividend status of GENMAB A/S?
GE9.DE does not pay a dividend.
How is the ChartMill rating for GENMAB A/S?
GE9.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about GENMAB A/S (GE9.DE) stock?
27 analysts have analysed GE9.DE and the average price target is 307.95 EUR. This implies a price increase of 30.88% is expected in the next year compared to the current price of 235.3.
Is GENMAB A/S (GE9.DE) expected to grow?
The Revenue of GENMAB A/S (GE9.DE) is expected to grow by 18.34% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for GENMAB A/S?
GENMAB A/S (GE9.DE) will report earnings on 2026-05-07.